
Formats: [HTML](/news/2017/06/8/the-u-s-food-and-drug-administration-asks-pharmaceutical-manufacturer-endo-international-plc-to-withdraw-its-long-lasting-12-hours-opioid.html)  [JSON](/news/2017/06/8/the-u-s-food-and-drug-administration-asks-pharmaceutical-manufacturer-endo-international-plc-to-withdraw-its-long-lasting-12-hours-opioid.json)  [XML](/news/2017/06/8/the-u-s-food-and-drug-administration-asks-pharmaceutical-manufacturer-endo-international-plc-to-withdraw-its-long-lasting-12-hours-opioid.xml)  

### [2017-06-8](/news/2017/06/8/index.md)

##### Opioid epidemic
# The U.S. Food and Drug Administration asks pharmaceutical manufacturer Endo International plc to withdraw its long-lasting (12 hours) opioid painkiller, Opana ER, from the market after an FDA panel concluded the drug's benefits no longer outweighed the risks of abuse. Endo is evaluating its options. 




### Sources:

1. [Reuters](https://www.reuters.com/article/us-endo-intl-opana-fda-idUSKBN18Z2SQ)
1. [Cover Image](https://s4.reutersmedia.net/resources/r/?m=02&d=20170608&t=2&i=1188215462&w=&fh=545px&fw=&ll=&pl=&sq=&r=LYNXMPED571UT)

### Changes:

1. [Opioid epidemic: The U.S. Food and Drug Administration asks pharmaceutical manufacturer Endo International plc to withdraw its long-lasting (12 hours) opioid painkiller, Opana ER, from the market after an FDA panel concluded the drug's benefits no longer outweighed the risks of abuse. Endo is evaluating its options. ](/news/2017/06/8/opioid-epidemic-the-u-s-food-and-drug-administration-asks-pharmaceutical-manufacturer-endo-international-plc-to-withdraw-its-long-lasting.md) _2018-02-06 13:49:30 (First version)_
1. [The U.S. Food and Drug Administration asks pharmaceutical manufacturer Endo International plc to withdraw its long-lasting (12 hours) opioid painkiller, Opana ER, from the market after an FDA panel concluded the drug's benefits no longer outweighed the risks of abuse. Endo is evaluating its options. ](/news/2017/06/8/the-u-s-food-and-drug-administration-asks-pharmaceutical-manufacturer-endo-international-plc-to-withdraw-its-long-lasting-12-hours-opioid.md) _(Current version)_

### Related:

1. [The U.S. Federal Trade Commission files an anti-trust suit against Endo Pharmaceuticals, Inc., and several other drug companies for using pay-for-delay settlements to block consumers' access to lower-cost generic versions of pain medications, Opana ER and Lidoderm. ](/news/2016/03/31/the-u-s-federal-trade-commission-files-an-anti-trust-suit-against-endo-pharmaceuticals-inc-and-several-other-drug-companies-for-using-pa.md) _Context: Endo International plc, Opana ER_
2. [Tom Wolf, the Governor of Pennsylvania, issues a disaster declaration over the "heroin and opioid epidemic", starting an Opioid Operational Command Center at the Pennsylvania Emergency Management Agency. ](/news/2018/01/10/tom-wolf-the-governor-of-pennsylvania-issues-a-disaster-declaration-over-the-heroin-and-opioid-epidemica-starting-an-opioid-operationa.md) _Context: opioid epidemic_
3. [The United States Centers for Disease Control and Prevention reports life expectancy in 2016 in America declined for the second year in a row because of the opioid crisis. ](/news/2017/12/21/the-united-states-centers-for-disease-control-and-prevention-reports-life-expectancy-in-2016-in-america-declined-for-the-second-year-in-a-ro.md) _Context: opioid epidemic_
4. [A panel of external experts to the U.S. Food and Drug Administration unanimously vote that the benefits of the gene replacement treatment made by Spark Therapeutics of Philadelphia, Pennsylvania, called voretigene neparvovec (trade name, Luxturna), which treats Leber's congenital amaurosis (LCA), a form of hereditary blindness, outweigh its risks. The treatment, which targets a specific disease-causing mutation, is designed to treat individuals who have two mutated copies of a gene called "RPE65" and consists of a virus injected into the eye loaded with a normal copy of the "RPE65" gene. Further, this technique utilizing adeno-associated virus as a vector may, in the future, be used for the treatment of heart disease and also mutations other than LCA, including some cancers. ](/news/2017/10/12/a-panel-of-external-experts-to-the-u-s-food-and-drug-administration-unanimously-vote-that-the-benefits-of-the-gene-replacement-treatment-ma.md) _Context: Food and Drug Administration_
5. [The Food and Drug Administration has approved the first treatment that genetically engineers patients' own blood cells to destroy acute lymphoblastic leukemia. The approval makes Novartis the proprietor of the first gene therapy to hit the U.S. market. ](/news/2017/08/30/the-food-and-drug-administration-has-approved-the-first-treatment-that-genetically-engineers-patients-own-blood-cells-to-destroy-acute-lymp.md) _Context: Food and Drug Administration_
